A Phase III Randomized Double-Blind Multi-Center Treat-Through Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Children Aged 2-17 Years With Moderately to Severely Active Crohn's Disease
Latest Information Update: 20 Jul 2026
At a glance
- Drugs Afimkibart (Primary) ; Afimkibart (Primary)
- Indications Crohn's disease
- Focus Registrational; Therapeutic Use
- Acronyms SIBERITE-PEDS
- Sponsors Roche
Most Recent Events
- 13 Jul 2026 Planned initiation date changed from 30 Jun 2026 to 31 Aug 2026.
- 12 Jun 2026 Planned initiation date changed from 29 May 2026 to 30 Jun 2026.
- 15 May 2026 Status changed from not yet recruiting to recruiting.